Cargando…

HLA Antibody Rates Are Not Increased in a Regional Group of Male COVID-19 Convalescent Plasma Donors

Detalles Bibliográficos
Autores principales:	Juskewitch, Justin E., Senefeld, Jonathon W., Johnson, Patrick W., Mills, John R., Joyner, Michael J., Gandhi, Manish J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Mayo Foundation for Medical Education and Research 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8376709/ https://www.ncbi.nlm.nih.gov/pubmed/34607639 http://dx.doi.org/10.1016/j.mayocp.2021.08.004

Ejemplares similares

Elevated Rate of HLA Antibodies in Male COVID-19 Convalescent Plasma Donors: A Risk Factor for Transfusion-Related Acute Lung Injury
por: Juskewitch, Justin E., et al.
Publicado: (2021)

Convalescent plasma to deliver therapeutic antibodies against COVID-19
por: Senefeld, Jonathon W., et al.
Publicado: (2022)

Vaccine-boosted convalescent plasma therapy for patients with immunosuppression and COVID-19
por: Ripoll, Juan G., et al.
Publicado: (2022)

Coagulation profile of human COVID-19 convalescent plasma
por: Klompas, Allan M., et al.
Publicado: (2022)

Late Treatment for COVID-19 With Convalescent Plasma
por: Senefeld, Jonathon W., et al.
Publicado: (2022)

In Reply—How Safe Is COVID-19 Convalescent Plasma?
por: Joyner, Michael J., et al.
Publicado: (2021)

Convalescent plasma use in the USA was inversely correlated with COVID-19 mortality
por: Casadevall, Arturo, et al.
Publicado: (2021)

Recruitment Strategy for Potential COVID-19 Convalescent Plasma Donors
por: Andersen, Kylie J., et al.
Publicado: (2020)

Convalescent plasma for COVID-19 in oncohematological patients: a call for revision of the European Conference on Infections in Leukemia-9 (ECIL-9) guidelines
por: Focosi, Daniele, et al.
Publicado: (2023)

In Reply — Limitations of Safety Update on Convalescent Plasma Transfusion in COVID-19 Patients
por: Joyner, Michael. J., et al.
Publicado: (2020)

Convalescent Plasma Use in the United States was inversely correlated with COVID-19 Mortality: Did Plasma Hesitancy cost lives?
por: Casadevall, Arturo, et al.
Publicado: (2021)

COVID-19 Convalescent Plasma for the Treatment of Immunocompromised Patients: A Systematic Review and Meta-analysis
por: Senefeld, Jonathon W., et al.
Publicado: (2023)

Guidance on the Use of Convalescent Plasma to Treat Immunocompromised Patients With Coronavirus Disease 2019
por: Bloch, Evan M, et al.
Publicado: (2023)

In Reply — Micro-Thrombosis, Perfusion Defects, and Worsening Oxygenation in COVID-19 Patients: A Word of Caution on the Use of Convalescent Plasma
por: Klompas, Allan M., et al.
Publicado: (2021)

Convalescent Plasma for Infectious Diseases: Historical Framework and Use in COVID-19
por: Ripoll, Juan G., et al.
Publicado: (2021)

Case Studies in Physiology: Male to female transgender swimmer in college athletics
por: Senefeld, Jonathon W., et al.
Publicado: (2023)

Use of convalescent plasma in COVID‐19 patients with immunosuppression
por: Senefeld, Jonathon W., et al.
Publicado: (2021)

Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19
por: Joyner, Michael J., et al.
Publicado: (2021)

Mortality in individuals treated with COVID-19 convalescent plasma varies with the geographic provenance of donors
por: Kunze, Katie L., et al.
Publicado: (2021)

Convalescent Plasma Therapy for COVID-19: A Graphical Mosaic of the Worldwide Evidence
por: Klassen, Stephen A., et al.
Publicado: (2021)

SARS-COV-2 Triggers the Development of Class I and Class II HLA Antibodies in Recovered Convalescent Plasma Donors
por: Dada, Ashraf, et al.
Publicado: (2022)

The Role of Disease Severity and Demographics in the Clinical Course of COVID-19 Patients Treated With Convalescent Plasma
por: Ma, Tengfei, et al.
Publicado: (2022)

Limited Correlation between SARS-CoV-2 Serologic Assays for Identification of High-Titer COVID-19 Convalescent Plasma Using FDA Thresholds
por: Larkey, Nicholas E., et al.
Publicado: (2022)

Dynamics of antibodies to SARS‐CoV‐2 in convalescent plasma donors
por: Steenhuis, Maurice, et al.
Publicado: (2021)

Antibody indexes in COVID-19 convalescent plasma donors: Unanswered questions
por: Bonetti, Tatiana Carvalho de Souza, et al.
Publicado: (2021)

Use of convalescent plasma in the treatment of COVID-19
por: Joyner, Michael J., et al.
Publicado: (2023)

Implications of Coronavirus Disease 2019 (COVID-19) Antibody Dynamics for Immunity and Convalescent Plasma Therapy
por: Casadevall, Arturo, et al.
Publicado: (2020)

HLA and red blood cell antigen genotyping in SARS-CoV-2 convalescent plasma donors
por: Lemieux, William, et al.
Publicado: (2023)

Analysis of anti-Omicron neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources
por: Sullivan, David J, et al.
Publicado: (2022)

Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19
por: Thompson, Michael A., et al.
Publicado: (2021)

Plasma after both SARS-CoV-2 boosted vaccination and COVID-19 potently neutralizes BQ.1.1 and XBB.1
por: Sullivan, David J, et al.
Publicado: (2022)

Plasma after both SARS-CoV-2 boosted vaccination and COVID-19 potently neutralizes BQ.1.1 and XBB.1
por: Sullivan, David J., et al.
Publicado: (2023)

Longitudinal SARS-CoV-2 Seroconversion Course and Antibody Levels by Blood Groups in Convalescent Plasma Donors in Turkey
por: Karaca, Aziz, et al.
Publicado: (2021)

The Effect of Convalescent Plasma Therapy on Mortality Among Patients With COVID-19: Systematic Review and Meta-analysis
por: Klassen, Stephen A., et al.
Publicado: (2021)

Dynamics of anti-SARS-CoV-2 antibodies in repeat convalescent plasma donors
por: Franchini, Massimo, et al.
Publicado: (2021)

Convalescent plasma for COVID-19. TSUNAMI is not the final word
por: Franchini, Massimo, et al.
Publicado: (2022)

Associations Between Symptoms, Donor Characteristics and IgG Antibody Response in 2082 COVID-19 Convalescent Plasma Donors
por: Vinkenoog, Marieke, et al.
Publicado: (2022)

Appropriate selection of convalescent plasma donors for COVID-19
por: Tedder, Richard S, et al.
Publicado: (2021)

Screening for SARS‐CoV‐2 antibodies in convalescent plasma in Brazil: Preliminary lessons from a voluntary convalescent donor program
por: Wendel, Silvano, et al.
Publicado: (2020)

The predictors of high titer of anti-SARS-CoV-2 antibody of convalescent plasma donors
por: Wardhani, Shinta Oktya, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rl1bqa5sfhvipefpqln0sq0kpi